Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alteogen Inc (196170)
The Alteogen share price today is 316,500, view KQ 196170 stock exchange data. Track the latest Alteogen share price with real-time updates on 196170 stock performance including market cap, day range, 52-week range and dividend yield. Access 196170 charts, earnings dates and analyst estimates to support your investment decisions.
316,500
-7,500(-2.31%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
314,000
344,000
52 wk Range
286,000
569,000
196170 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
314,000344,000
52 wk Range
286,000569,000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.12%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.12%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
196170 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
458,000
Upside
+44.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 458,000
(+44.71% Upside)
Earnings
Latest Release
08-05-2026
EPS / Forecast
903.49 / 700.05
Revenue / Forecast
71.6B / 88.41B
Compare 196170 to Peers and Sector
Metrics to compare | 196170 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship196170PeersSector | |
|---|---|---|---|---|
P/E Ratio | 133.3x | −31.2x | −0.4x | |
PEG Ratio | −8.58 | −0.45 | 0.00 | |
Price/Book | 34.4x | 2.3x | 2.6x | |
Price / LTM Sales | 85.2x | 8.0x | 3.0x | |
Upside (Analyst Target) | 53.1% | 36.3% | 51.5% | |
Fair Value Upside | Unlock | −0.2% | 8.8% | Unlock |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Alteogen (196170) Share Price Today?
The Alteogen share price today is 3,16,500.
What is the current Alteogen (196170) share price and day range?
As of 13-07-2026, the Alteogen share price is 3,16,500, with a previous close of 3,24,000. The share price has ranged from 3,14,000 to 3,44,000 today, while the 52-week range spans from 2,86,000 to 5,69,000.
What Is the Alteogen Market Cap?
As of today, Alteogen market cap is 17.35T.
Does Alteogen Pay Dividends? What's The Current Dividend Yield?
The Alteogen dividend yield is 0.12%.
What Is the Alteogen (196170) Share Price Target?
The average 12-month share price target for Alteogen is 4,58,000, with a high estimate of 620000 and a low estimate of 250000. 4 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +44.71% Upside potential.
What Is Alteogen's Earnings Per Share (TTM)?
The Alteogen EPS (TTM) is 1,960.
When Is the Next Alteogen Earnings Date?
Alteogen will release its next earnings report on 19-08-2026.
From a Technical Analysis Perspective, Is 196170 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Alteogen Trade On?
Alteogen is listed and trades on the KOSDAQ.
What Is the Stock Symbol for Alteogen?
The stock symbol for Alteogen is "196170."
How Many Times Has Alteogen Stock Split?
Alteogen has split 4 times.
How Many Employees Does Alteogen Have?
Alteogen has 172 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.